semaglutide patent india Expiry in 2026: Why Is On the Pharma Radar Why Sun Pharma's semaglutide approval

Key outcomes identified by the patient advocacy groups as important to patients with overweight or obesity were weight loss, reducing weight-related comorbidity, and improving HRQoL

During a call with analysts on Thursday, executives said the group would keep investing in its cloud division, which will continue to be managed by its own chief executive and board of directors as originally envisioned during a corporate overhaul first announced in March

Some patients anecdotally report that the timing of their Zepbound injection affects their symptoms

We systematically extracted the metabolism characteristics of 207 of the most widely prescribed oral medications in the United States

PA is not required for type 2 diabetes

Curious about the ENT-related side effects of GLP-1 receptor agonists (i.e